- Cancer is one of the most devastating things
that can happen.
So the earlier that we can detect tumors,
the greater chance we have
for increasing patient survivorship.
Once we know that there's a cancer,
then we actually approach how we use
various modalities of treatment, whether it's a surgery,
whether it's chemotherapy, immunotherapy
and combining that with radiation therapy.
Varian as a company has one simple goal.
It's a world without a fear of cancer.
We are now becoming much more an oncology company,
we have a comprehensive cancer care,
but when it comes to what we actually do for patients,
now with Siemens Healthineers,
we offer solutions from early detection and diagnosis,
all the way through treatment and survivorship.
Approximately 50% of all cancer patients
require radiotherapy.
We know that tumors change over time.
They can also move from session to session,
as do the surrounding normal tissues
that we're trying to spare.
When changes are seen in the anatomy,
the oncologist is often faced with the decision,
to pause treatment for several days to re-plan
or continue with the current suboptimal plan.
So one of the greatest challenges in radiation oncology
is the ability to see at the time of the treatment
where the tumor is in relation to the normal organs
that we're trying to spare.
CT simulation images, the quality has improved
over the past several years,
but we've needed that improvement
at the treatment unit as well.
[Announcer] Introducing HyperSight,
our next generation of in-room imaging,
larger images, better contrast, faster cone beam CT imaging.
HyperSight, our FDA pending integrated in-room imaging
will go far beyond what's possible
with conventional radiotherapy systems.
For the first time, there will be in-room cone beam
CT imaging system that offers Hounsfield units
with accuracy expected from conventional CT simulators.
The improved contrast resolution makes it possible
to differentiate tissue organs
that to date could not be told apart.
That's what's made the difference
with this new technology that HyperSight will provide.
The ability to decrease PRV margins, for example,
on organs at risk,
with the better certainty of where those organs are,
we may be able to reduce those margins
and therefore increase the dose to the tumor target itself.
With the conventional technology,
image acquisition took 60 seconds.
With the HyperSight, we can do that
on Halcyon and Ethos in six seconds.
So we shave up 54 seconds of motion.
In the past, we would want to acquire images
with a breath hold where we tell patient don't breathe.
Well, doing that over 60 seconds is really hard.
Doing it within six seconds,
we think that every patient can accommodate that.
I think there are small steps and improvements
that we make in technology in the field every year.
This is honestly a paradigm shift.
It's not just improvement in image quality,
it's the ability to adapt a treatment plan
at the same time in that session
with confidence and accuracy,
because of the improved image quality.
That's the paradigm shift.
This is an epic advancement
in image quality, precision and speed.
HyperSight technology will be deployed
in certain Varian systems,
starting first with Halcyon platform and Ethos therapy,
followed by our TrueBeam and Edge systems.
- New technology is definitely decreasing
the fear of cancer for patients and their families.
We've gotten word from public and patients and families
reaching out with hope.
The emails were literally entitled Hope.